Skip to main content

Advertisement

ADVERTISEMENT

Videos

William Gray, MD: Critique of the New Paclitaxel Meta-Analysis by Katsanos
Videos
01/24/2020
William Gray, MD, offers a critique of the design and findings of the study published by Katsanos and colleagues in January 2020 in the Journal of Vascular and Interventional Radiology
William Gray, MD, offers a critique of the design and findings of the study published by Katsanos and colleagues in January 2020 in the Journal of Vascular and Interventional Radiology
William Gray, MD, offers a...
01/24/2020
Vascular Disease Management
Comparative Outcomes of Supera vs Bare Nitinol Stents in FemPop Disease: Insights From the XLPAD Registry
Meeting Exclusives
01/24/2020
Hollywood, FL (January 24, 2020) – The Supera stent (Abbott Vascular) is a “fundamentally different design”, said Bret Wiechmann, MD, of Vascular & Interventional Physicians in Gainesville, Florida, in his Friday morning presentation on the...
Hollywood, FL (January 24, 2020) – The Supera stent (Abbott Vascular) is a “fundamentally different design”, said Bret Wiechmann, MD, of Vascular & Interventional Physicians in Gainesville, Florida, in his Friday morning presentation on the...
Hollywood, FL (January 24, 2020)...
01/24/2020
Vascular Disease Management
01/24/2020
Michael R. Jaff, DO, Vice President of Clinical Affairs, Innovation, Technology and Peripheral Interventions at Boston Scientific, presented results from the COMPARE Pilot randomized clinical trial on Friday morning at the International...
Michael R. Jaff, DO, Vice President of Clinical Affairs, Innovation, Technology and Peripheral Interventions at Boston Scientific, presented results from the COMPARE Pilot randomized clinical trial on Friday morning at the International...
Michael R. Jaff, DO, Vice...
01/24/2020
Vascular Disease Management
01/23/2020
The study design of a recently published meta-analysis by Katasanos and colleagues is flawed, according to a critique presented by William Gray, MD, at the International Symposium on Endovascular Therapy (ISET).
The study design of a recently published meta-analysis by Katasanos and colleagues is flawed, according to a critique presented by William Gray, MD, at the International Symposium on Endovascular Therapy (ISET).
The study design of a recently...
01/23/2020
Vascular Disease Management
01/23/2020
Hollywood, FL (January 23, 2020)- Results of the IN.PACT DEEP Global study show durable effectiveness and safety of the IN.PACT Admiral drug-coated balloon (DCB) (Medtronic) through 4 years, according to data presented by Gunnar Tepe, MD, at...
Hollywood, FL (January 23, 2020)- Results of the IN.PACT DEEP Global study show durable effectiveness and safety of the IN.PACT Admiral drug-coated balloon (DCB) (Medtronic) through 4 years, according to data presented by Gunnar Tepe, MD, at...
Hollywood, FL (January 23,...
01/23/2020
Vascular Disease Management
01/23/2020
Hollywood, FL (January 23, 2020) – In the first and only head-to-head comparison of two paclitaxel-eluting stents used in peripheral intervention, no difference was seen for the primary endpoint of primary patency at 24 months. Clinical...
Hollywood, FL (January 23, 2020) – In the first and only head-to-head comparison of two paclitaxel-eluting stents used in peripheral intervention, no difference was seen for the primary endpoint of primary patency at 24 months. Clinical...
Hollywood, FL (January 23, 2020)...
01/23/2020
Vascular Disease Management
Meeting Exclusives
01/23/2020
The Stellarex drug-coated balloon (DCB) (Philips) showed “excellent” safety and effectiveness in a real-world population of patients with complex peripheral artery disease (PAD).
The Stellarex drug-coated balloon (DCB) (Philips) showed “excellent” safety and effectiveness in a real-world population of patients with complex peripheral artery disease (PAD).
The Stellarex drug-coated...
01/23/2020
Vascular Disease Management
01/23/2020
Findings from 7 different real-world data sources show no difference in survival following treatment with drug-coated and non-drug-coated devices, according to a presentation given today at the International Symposium on Endovascular Therapy...
Findings from 7 different real-world data sources show no difference in survival following treatment with drug-coated and non-drug-coated devices, according to a presentation given today at the International Symposium on Endovascular Therapy...
Findings from 7 different...
01/23/2020
Vascular Disease Management
01/23/2020
Hollywood, FL (January 23, 2020) – In a pooled analysis that included more than 1000 patients treated with the Lutonix 035 drug-coated balloon (DCB) (BD), no increase in mortality risk was seen compared to those treated with uncoated balloon...
Hollywood, FL (January 23, 2020) – In a pooled analysis that included more than 1000 patients treated with the Lutonix 035 drug-coated balloon (DCB) (BD), no increase in mortality risk was seen compared to those treated with uncoated balloon...
Hollywood, FL (January 23, 2020)...
01/23/2020
Vascular Disease Management
Treating From Below: A Physician Perspective on Pedal Access and the Lutonix® 018 DCB
Interview
01/21/2020
This article first appeared in Cath Lab Digest, Volume 27 - Issue 11 - November 2019  Can you tell us about your lab and practice?
This article first appeared in Cath Lab Digest, Volume 27 - Issue 11 - November 2019  Can you tell us about your lab and practice?
This article first appeared in...
01/21/2020
Vascular Disease Management

Advertisement

Advertisement

Advertisement